论文部分内容阅读
骨骼显象剂从七十年代起发展很快。~(85)Sr、~(87m)Sr、~(18)F等核素的骨骼显象剂已为~(99m)Tc核素螯合的无机磷及有机膦化合物所取代。三聚磷酸盐、多聚磷酸盐、焦磷酸盐、1-羟基-1,1二膦酸基乙烷二钠盐以及次甲基二膦酸(MDP)等放射性药物,在临床应用上均具有良好的性能。国外最近报导~(99m)Tc-MDP较多,认为它具有亲骨专一性强、血液清除率快、显影清晰、毒性低、不被肝脏所摄取等优点。此外,它亦可作为急性心肌梗塞部位的显象剂。
Bone developers have developed rapidly since the seventies. The skeletal imaging agents of ~ (85) Sr, ~ (87m) Sr, ~ (18) F and other nuclides have been replaced by ~ (99m) Tc nuclides chelated inorganic phosphorus and organic phosphine compounds. Radiopharmaceuticals such as tripolyphosphates, polyphosphates, pyrophosphates, 1-hydroxy-1,1 diphosphonic acid ethane disodium salt, and methyldiphosphonic acid (MDP) have in clinical application Good performance. Foreign recently reported ~ (99m) Tc-MDP more, that it has the pro-bone specificity, rapid blood clearance, clear imaging, low toxicity, not uptake by the liver and so on. In addition, it is also used as a developing agent for acute myocardial infarction.